中等度から重度の非増殖性糖尿病網膜症（NPDR）の改善における硝子体内（IVT）アフリベルセプトの有効性および安全性に関する研究

基本情報

NCT ID

NCT02718326

ステータス

完了

試験のフェーズ

第3相

試験タイプ

介入

目標被験者数

402

治験依頼者名

Regeneron Pharmaceuticals

概要

The primary objective of the study is to assess the efficacy of intravitreal (IVT) aflibercept compared to sham treatment in the improvement of moderately severe to severe nonproliferative diabetic retinopathy (NPDR). The secondary objectives of the study are: * To characterize the safety of IVT aflibercept in patients with moderately severe to severe NPDR * To determine if IVT aflibercept will prevent the worsening of diabetic retinopathy and reduce the incidence of DME * To determine the anatomic effects of IVT aflibercept in patients with moderately severe to severe NPDR

対象疾患

介入

依頼者（Sponsor）